#USA #San Diego #BioAge Labs #BIOA #Securities Act

BioAge Labs Investor Alert

In a significant development for investors of BioAge Labs, Inc. (NASDAQ: BIOA), the law firm Robbins Geller Rudman & Dowd LLP has announced an opportunity for those facing substantial losses to lead a class action lawsuit against the company. This move comes in light of substantial concerns following the company's recent clinical trial results.

Understanding the Lawsuit

The alert states that investors who purchased or acquired shares of BioAge Labs, specifically linked to the registration statement issued during the initial public offering (IPO) on September 26, 2024, must act quickly. The deadline for seeking appointment as the lead plaintiff in the class action lawsuit is March 10, 2025. The case, formally known as Soto v. BioAge Labs, Inc., No. 25-cv-00196 (N.D. Cal.), alleges that BioAge Labs and several of its executives violated the Securities Act of 1933.

BioAge Labs, a clinical-stage biopharmaceutical company, specializes in developing treatments for metabolic diseases. During its IPO, the firm sold 12.65 million shares at $18.00 each. However, the lawsuit claims that the offering documents were misleading, asserting there were no safety concerns related to the company's products. Particularly, these documents indicated an expectation of the company's ability to meet primary endpoints in its clinical trial related to the development of a drug called azelaprag.

The Fallout from Clinical Trials

Investors were handed alarming news when, on December 6, 2024, BioAge Labs announced the discontinuation of its ongoing STRIDES Phase 2 study. This decision came after several subjects experienced liver transaminitis while receiving azelaprag. Following this crucial setback, the company's stock price fell drastically by more than 76%, prompting concerns among investors.

At the time the class action lawsuit was filed, shares of BioAge Labs were trading at approximately $5.82, a stark decline from the original IPO price.

The Process for Lead Plaintiff

The Private Securities Litigation Reform Act of 1995 allows any investor who meets the criteria to seek appointment as the lead plaintiff in this class action. The lead plaintiff typically has the largest financial stake in the case and represents the interests of other class members. Notably, investors are not required to serve as lead plaintiff to benefit from any potential recovery.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is recognized as one of the premier firms specializing in representing investors in securities fraud cases. The firm has achieved substantial financial recoveries for investors, with a remarkable track record of success. In the last four years alone, it has managed to secure over $2.2 billion in monetary relief for its clients, significantly eclipsing other firms' achievements in the same period.

For more information on how to participate in the class action litigation, interested investors can visit their dedicated webpage or contact attorneys J.C. Sanchez or Jennifer N. Caringal at Robbins Geller directly.

Conclusion

With the March deadline approaching, investors affected by BioAge Labs' recent developments are encouraged to take immediate action. The class action lawsuit represents a critical opportunity for those who have experienced losses to not only seek justice but potentially recover some of their investments. It's essential for investors to stay informed and consider their options carefully.